Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure

Suggested Citation

Full Text

Reprint

José I Fernandez-Montequin,

Blas Y Betancourt,

Gisselle Leyva-Gonzalez,

Ernesto L Mola,

Katia Galan-Naranjo,

Mayte Ramirez-Navas,

Sergio Bermudez Rojas,

Felix Rosales,

Elizeth Garcia-Iglesias,

Jorge Berlanga-Acosta DVM MS PhD,

Ricardo Silva-Rodríguez PhD,

Marianela Garcia-Siverio,

Luis H Martinez

Published: November 10, 2009

ABSTRACT
Previous studies have shown that an epidermal growth factor-based formulation (Heberprot-P) can enhance granulation of high-grade diabetic foot ulcers (DFU). The aim of this study was to explore the clinical effects of this administration up to complete wound closure. A pilot study in 20 diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution was performed. Mean ulcer size was 16.3 ± 21.3 cm2. Intralesional injections of 75 μg of Heberprot-P three times per week were given up to complete wound healing. Full granulation response was achieved in all 20 patients in 23.6 ± 3.8 days. Complete wound closure was obtained in 17 (85%) cases in 44.3 ± 8.9 days. Amputation was not necessary in any case and only one relapse was notified. The most frequent adverse events were tremors, chills, pain and ardour at site of administration and local infection. The therapeutic scheme of intralesional Heberprot-P administration up to complete closure can be safe and suitable to improve the therapeutic goal in terms of healing of chronic DFU.

[http://www3.interscience.wiley.com/journal/122243440/abstract]

Fernández-Montequín JI, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. MEDICC Rev. 2009;11(4):40–43.